Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Autologous stem cell transplantation (ASCT) is an important component of treatment of multiple myeloma (MM). The post-ASCT setting offers a unique opportunity to increase myeloma specific immunity through enhancement of T and NK cell responses. The vast array of therapeutics being developed for MM, including cell-based therapies, dendritic vaccines, bispecific antibodies, and IL-15 agonists, provide the opportunity to increase tumor-specific immunity. Maintenance therapies, including immunomodulatory drugs, proteasome inhibitors, and daratumumab, exhibit a significant anti-myeloma response by modulating the immune system. Lenalidomide promotes an antitumoral immune microenvironment, whereas daratumumab can potentially cause NK cell fratricide. Thus, understanding the effects of commonly used maintenance drugs on the restoration of tumor specific immunity is important. In this review, we look at current and emerging therapeutics and their integration post-ASCT in the context of immune reconstitution to improve clinical responses in patients with MM. © 2021 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

Original languageEnglish (US)
Pages (from-to)61-69
Number of pages9
JournalTransplantation and Cellular Therapy
Issue number2
StatePublished - Feb 2022

Bibliographical note

Funding Information:
Financial disclosure: M.J. has received clinical research funding from Nektar Therapeutics and Fate Therapeutics and honoraria from Kyowa Kirin and Bristol Meyers Squibb. VB has research funding from Incyte, BMS, Gamida Cell, Dr.Reddy and FATE Therapeutics. VB is an Advisory Board member for Novartis, Karyopharma and Gamida.

Publisher Copyright:
© 2021


  • Bispecific antibodies
  • CART
  • Immune reconstitution
  • Multiple myeloma

PubMed: MeSH publication types

  • Journal Article
  • Review


Dive into the research topics of 'Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma'. Together they form a unique fingerprint.

Cite this